Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 6/20 | 0.35 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | GRM5 | P41594 | 1/20 | 0.33 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
| ▸ | ASPH | Q12797 | 1/20 | 0.31 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CES1 | P23141 | 1/20 | 0.31 |
| ▸ | PLA2G2D | Q9UNK4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29705532 | 1.00 | IDO1 (0.35) | IDO1DGAT2ALDH1A1GRM5ABHD6 | |
| SCHEMBL26916353 | 0.81 | KMT2A (0.46) | IDO1ALDH1A1GRM5ABHD6ATM | |
| SCHEMBL29498804 | 0.79 | NAPRT (0.46) | ALDH1A1DGAT1POLBHCAR2KDM4E | |
| SCHEMBL1516793 | 0.79 | NAPRT (0.46) | ALDH1A1DGAT1POLBHCAR2KDM4E | |
| SCHEMBL26023823 | 0.79 | DGAT1 (0.36) | DGAT2ALDH1A1GRM5DGAT1POLB | |
| SCHEMBL31356591 | 0.78 | OPRK1 (0.42) | DGAT2ALDH1A1DGAT1POLBHCAR2 | |
| SCHEMBL21815554 | 0.78 | ALDH1A1 (0.35) | DGAT2ALDH1A1GRM5DGAT1ATM | |
| SCHEMBL25335179 | 0.78 | DGAT1 (0.52) | ALDH1A1GRM5DGAT1POLBHCAR2 | |
| SCHEMBL9648890 | 0.78 | OPRK1 (0.42) | DGAT2ALDH1A1DGAT1POLBHCAR2 | |
| SCHEMBL24529420 | 0.77 | IDO1 (0.37) | IDO1DGAT2ALDH1A1ABHD6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250282781-A1 | APOL1 INHIBITORS AND METHODS OF USE | HERCULES CAPITAL, INC., AS AGENT | 2025-09-11 | — | — | US | disclosed |
| US-12344610-B2 | APOL1 inhibitors and methods of use | MAZE THERAPEUTICS, INC. (US) | 2025-07-01 | — | — | US | disclosed |
| WO-2024249254-A2 | METHODS OF USING APOL1 INHIBITORS | MAZE THERAPEUTICS, INC. (US) | 2024-12-05 | — | — | WO | disclosed |
| US-20240400565-A1 | APOL1 INHIBITORS AND METHODS OF USE | HERCULES CAPITAL, INC., AS AGENT | 2024-12-05 | — | — | US | disclosed |
| EP-4465982-A2 | APOL1 INHIBITORS AND METHODS OF USE | Maze Therapeutics, Inc. (US) | 2024-11-27 | — | — | EP | disclosed |
| US-20240150345-A1 | GCN2 MODULATING COMPOUNDS AND USES THEREOF | PHARMARON UK LTD. (GB) | 2024-05-09 | — | — | US | disclosed |
| US-11976067-B2 | APOL1 inhibitors and methods of use | MAZE THERAPEUTICS, INC. (US) | 2024-05-07 | — | — | US | disclosed |
| WO-2024091538-A1 | COMPOUNDS AND COMPOSITIONS AS GPR52 MODULATORS | NEUROCRINE BIOSCIENCES, INC. (US) | 2024-05-02 | — | — | WO | disclosed |
| WO-2024091541-A1 | COMPOUNDS AND COMPOSITIONS AS GPR52 MODULATORS | NEUROCRINE BIOSCIENCES, INC. (US) | 2024-05-02 | — | — | WO | disclosed |
| WO-2024091541-A1 | COMPOUNDS AND COMPOSITIONS AS GPR52 MODULATORS | NEUROCRINE BIOSCIENCES, INC. (US) | 2024-05-02 | — | — | WO | disclosed |
| US-20230265096-A1 | APOL1 INHIBITORS AND METHODS OF USE | HERCULES CAPITAL, INC., AS AGENT | 2023-08-24 | — | — | US | disclosed |
| US-20230265096-A1 | APOL1 INHIBITORS AND METHODS OF USE | HERCULES CAPITAL, INC., AS AGENT | 2023-08-24 | — | — | US | disclosed |
| US-20230265096-A1 | APOL1 INHIBITORS AND METHODS OF USE | HERCULES CAPITAL, INC., AS AGENT | 2023-08-24 | — | — | US | disclosed |
| WO-2023141432-A2 | APOL1 INHIBITORS AND METHODS OF USE | MAZE THERAPEUTICS, INC. (US) | 2023-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265096-A1 | APOL1 INHIBITORS AND METHODS OF USE | APOL1, APOB, LDLR | IDO1 2326/4885DGAT2 4003/4885ALDH1A1 2642/4885 |
| US-12344610-B2 | APOL1 inhibitors and methods of use | APOL1, APOB, PON1 | IDO1 2211/4885DGAT2 3996/4885ALDH1A1 2427/4885 |
| US-20240150345-A1 | GCN2 MODULATING COMPOUNDS AND USES THEREOF | EIF2AK4, GCN1, CLN6 | IDO1 4654/4885DGAT2 275/4885ALDH1A1 4164/4885 |
| US-11976067-B2 | APOL1 inhibitors and methods of use | APOL1, APOB, LDLR | IDO1 2326/4885DGAT2 4003/4885ALDH1A1 2642/4885 |
| US-20250282781-A1 | APOL1 INHIBITORS AND METHODS OF USE | APOL1, APOB, PON1 | IDO1 2211/4885DGAT2 3996/4885ALDH1A1 2427/4885 |
| US-20240400565-A1 | APOL1 INHIBITORS AND METHODS OF USE | APOL1, APOB, PON1 | IDO1 2211/4885DGAT2 3996/4885ALDH1A1 2427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.